Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: A systematic review and mixed treatment comparison

Newman Clinical Research Professor, St Vincent's University Hospital, University College Dublin, Ireland.
Current Medical Research and Opinion (Impact Factor: 2.65). 11/2013; 26(4). DOI: 10.1185/03007995.2013.863755
Source: PubMed


Currently, direct comparative evidence or head-to-head data between BG-12 (dimethyl fumarate) and other disease-modifying treatments (DMTs) is limited. This study is a systematic review and data synthesis of published randomized clinical trials comparing the efficacy and safety of existing DMTs to BG-12 for relapsing-remitting multiple sclerosis (RRMS).

A systematic review was conducted by searching MEDLINE, EMBASE, and the Cochrane Library for English-language publications from 1 January 1960 to 15 November 2012., metaRegister of Controlled Trials, and conference proceedings from relevant annual symposia were also hand searched. Two independent reviewers collected and extracted data, with discrepancies reconciled by a third reviewer. Included studies were randomized controlled trials (RCTs) of DMTs (interferon [IFN] beta-1a, IFN beta-1b, glatiramer acetate [GA], BG-12, fingolimod, natalizumab, and teriflunomide) in adults with RRMS. Mixed treatment comparisons were conducted to derive the relative effect size for the included treatments. Annualized relapse rate (ARR), disability progression, and safety outcomes were assessed.

BG-12 240 mg twice a day (BID) significantly reduces ARR compared to placebo (rate ratio: 0.529 [95% CI: 0.451-0.620]), IFNs (0.76 [95% CI: 0.639-0.904]), GA (0.795 [95% CI: 0.668-0.947]), and teriflunomide 7 mg and 14 mg (0.769 [95% CI: 0.610-0.970] and 0.775 [95% CI: 0.614-0.979]), and does not show a significant difference when compared to fingolimod. Only natalizumab was significantly superior to BG-12 in reducing ARR. BG-12 also demonstrated favorable results for disability and safety outcomes.

Based on indirect comparison, BG-12 offers an effective oral treatment option for patients with RRMS with an overall promising efficacy and safety profile compared to currently approved DMTs. Key limitations of the systematic review were the large heterogeneity in patients enrolled and the variability in the definition of outcomes in included trials.

Download full-text


Available from: Michael Hutchinson, Jan 22, 2014
  • Source
    • "It was similar in efficacy to fingolimod. Natalizumab was the most effective agent [40]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Autoimmune diseases are the diseases of the modern century. Due to their complicated pathogenesis and the enrollment of many factors in disease initiation and progression, these diseases are considered uneasy to treat. Immune cells exist normally in our bodies. They are extremely essential for our survival against many pathogenic and foreign particles. Manipulating these cells through chemical and biological drugs has tremendous effects, usually with risks outweighing the benefits, as a result of the disturbance of cellular defense mechanisms. This chapter is devoted to the description of two different autoimmune diseases; multiple sclerosis (MS) and psoriasis. Up to date there is no known cure for MS and psoriasis. The available treatments approved by the FDA are mainly considered symptom relieving drugs and their major therapeutic action is only to slow the disease progression, and they lack the ability to eliminate the disease completely. A great devotion in this chapter was given to discuss several aspects regarding fumarate acid esters (FAEs) including; pharmacokinetics, mode of action, recommendations and specifically their potential as an effective treatment for psoriasis and MS.
    Full-text · Chapter · Jan 2015
  • Source
    • "[40] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Drugs (medicines) are considered either the primary therapy or an adjunct to another modality. Physicians of all specialties prescribe drugs on a daily basis, and therefore they need to understand the mode and action by which drugs exert their therapeutic effects. Written records of the use of natural products as medicinal agents date back thousands of years. However, it was not until the early 1800s that the active principles from plants were isolated. Since then thousands of drugs have been introduced to the drugs market. With advances in drug design, molecular biology and genetics, the rate of developing new potent drugs is accelerated. Due to the vast progress in drug development and discovery, medical and pharmacy students, doctors, nurses and pharmacists in training need to learn the principles of therapeutics in order to follow up with the frequent changes in the therapeutics and adapt to them. With contributions from some of my colleagues, this book provides a clear and concise overview of the most important commonly used drugs with emphasis on the pharmacology aspects necessary for a basic understanding of the subject. It reviews the concepts, clinical applications, dosage forms, bioavailability, pharmacokinetics and side effects of a large number of drugs used to alleviate pain, lower cholesterol levels, and treat bacterial infections, diabetes, osteoporosis, bleeding, psoriasis and multiple Sclerosis. This book, with over 750 references, is an excellent pharmacology text for the student who is looking to broaden his/her strengths prior to the exam. The beauty of this text is that it includes essential pharmacology concepts in a compact book that can be quickly referenced and read multiple times during the course of a student's studies. In addition, this guide assists scientists trained in molecular biology, medicinal chemistry and related fields who need to know the basic theories, principles and practical applications of pharmacology. With the addition of pharmacokinetics coverage, ways to improve the bioavailability of commonly used drugs and sections on therapeutics that will help readers identify with diseases and drug treatments, this book provides better preparation of researchers in the basics of pharmacology.
    Full-text · Book · Jan 2015
  • Source
    • "In EAE models it mildly reduced clinical scores in late phases of EAE in C57BL/6 mice, which were ascribed to an increase of Nrf2-dependent (nuclear factor (erythroid-derived 2) related factor-2) upregulations of antioxidative genes (Linker et al., 2011). Compared with fingolimod its efficacy in preclinical models was rather low, but clinical trials revealed a surprisingly strong reduction of active magnetic resonance imaging (MRI) lesions and reduction of the relapse rate (Hutchinson et al., 2014). Despite recent success with fingolimod and dimethyl fumarate there is still a high clinical need for novel disease modifying drugs particularly for the treatment of primary or SPMS and the natural sources of these drugs encourage the search for drug candidates among effective compositions of traditional medicines. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The association between vitamin D and multiple sclerosis has (re)-opened new interest in nutrition and natural compounds in the prevention and treatment of this neuroinflammatory disease. The dietary amount and type of fat, probiotics and biologicals, salmon proteoglycans, phytoestrogens and protease inhibitor of soy, sodium chloride and trace elements, and fat soluble vitamins including D, A and E were all considered as disease-modifying nutraceuticals. Studies in experimental autoimmune encephalomyelitis mice suggest that poly-unsaturated fatty acids and their 'inflammation-resolving' metabolites and the gut microflora may reduce auto-aggressive immune cells and reduce progression or risk of relapse, and infection with whipworm eggs may positively change the gut-brain communication. Encouraged by the recent interest in multiple sclerosis-nutrition nature's pharmacy has been searched for novel compounds with anti-inflammatory, immune-modifying and antioxidative properties, the most interesting being the scorpion toxins that inhibit specific potassium channels of T cells and antioxidative compounds including the green tea flavonoid epigallocatechin-3-gallate, curcumin and the mustard oil glycoside from e.g. broccoli, sulforaphane. They mostly also inhibit pro-inflammatory signaling through NF-κB or toll-like receptors and stabilize the blood brain barrier. Disease modifying functions may also complement analgesic and anti-spastic effects of cannabis, its constituents, and of 'endocannabinoid enhancing' drugs or nutricals like inhibitors of fatty acid amide hydrolase. Nutricals will not solve multiple sclerosis therapeutic challenges but possibly support pharmacological interventions or unearth novel structures. Copyright © 2014. Published by Elsevier Inc.
    Full-text · Article · Nov 2014 · Pharmacology [?] Therapeutics
Show more